debt_leverage_profile
0.00x Total Debt / Equity (Conservative)
High
SEC-XBRL
interest_rate_sensitivity
Low sensitivity; Arbutus carries minimal long-term debt (~$0 drawn credit facility), funded primarily by equity raises and licensing milestones
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) U.S.-China LNP lipid component sourcing; 2) Canadian single-site cGMP manufacturing reliance for clinical-stage materials
Inferred
Agent_Inference
international_expansion_readiness
Minimal direct international revenue; licensing royalties from Genevant/partners denominated in USD, negligible FX devaluation exposure
Inferred
Agent_Inference
geographic_footprint
Operations concentrated in Burnaby, BC Canada and U.S. partnerships; revenue USD-denominated, limiting sovereign currency devaluation risk materially
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High; Genevant Sciences is sole licensee of LNP platform, representing non-substitutable commercialization partner for delivery technology royalties
Inferred
Agent_Inference
business_model_type_primary
Cloud disruption impact minimal; Arbutus is a clinical-stage biotech—core value resides in IP and lab operations, not cloud-dependent SaaS delivery
Inferred
Agent_Inference
business_model_type_secondary
Secondary R&D data management on cloud adds 30-60 day migration risk but no revenue interruption; pipeline continuity unaffected
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; Arbutus is not a software company—partnerships are IP licensing agreements with high contractual switching costs for licensees
Inferred
Agent_Inference
howey_test_risk_index
Negligible Howey risk; revenue model is pharmaceutical IP licensing and milestone payments, not an investment contract or token offering
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Low-moderate; clinical trial patient data subject to GDPR (EU trials) and HIPAA, but CCPA exposure limited given no direct consumer data collection
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; operates in fragmented HBV/RNA therapeutics niche, holds IP but lacks dominant market share in any defined commercial market
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~100% transactional/milestone-based; revenue from licensing milestones, royalties, and collaboration payments—no recurring subscription contracts
Inferred
Agent_Inference
monetization_vector
IP licensing royalties (LNP patents via Genevant) plus clinical collaboration milestones; one-time and milestone payments dominate revenue mix
Inferred
Agent_Inference
pricing_architecture
Patent royalty rate-based pricing (typically 1-5% of net sales); milestone gates tied to clinical/regulatory events—limited pricing flexibility until commercialization
Inferred
Agent_Inference
pricing_power_rating
Moderate; LNP patent portfolio creates defensible pricing leverage, but licensees (large pharma) have significant negotiating power offsetting royalty maximization
Inferred
Agent_Inference
target_gross_margin_bracket
85-95% gross margin on licensing/royalty revenue; R&D expenses are OpEx, not COGS, yielding near-pure-margin IP monetization when milestones are recognized
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider problem; LNP technology is patent-protected—unauthorized use actionable (see Moderna litigation); licensee churn low given sunk development costs
Inferred
Agent_Inference
headcount_cost_structure
Sublinear; doubling licensing revenue requires minimal headcount addition—IP and legal overhead scale slowly; ~80 FTEs support full pipeline
Inferred
Agent_Inference
marginal_cost_of_growth
Near-zero marginal cost for additional royalty revenue on existing licensed patents; incremental pipeline programs add fixed R&D burn, not variable cost
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; Arbutus does not operate a franchise network
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale (full LNP royalty commercialization), CAC remains near-zero—demand is inbound from pharma developers needing LNP delivery IP
Inferred
Agent_Inference
network_effect_present
Weak network effects; LNP platform value grows with more validated use-cases (e.g., mRNA vaccines) but adoption doesn't compound users attracting more users
Inferred
Agent_Inference
asset_efficiency_ratio
-67.4% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate-high resilience; HBV/oncology treatments are non-discretionary, and large pharma licensing partners maintain R&D spend through recessions
Inferred
Agent_Inference
customer_segment_primary
Large pharmaceutical and biotechnology companies licensing LNP delivery technology for mRNA/RNAi therapeutics (e.g., Moderna, Pfizer-adjacent licensees)
Inferred
Agent_Inference
customer_segment_secondary
Academic/government research institutions accessing LNP technology for preclinical programs; lower revenue contribution but validates platform breadth
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.0% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001447028
High
SEC-EDGAR
ticker
ABUS
High
SEC-EDGAR